RE: Validation of the brazilian version of the expanded prostate cancer index composite (EPIC) for patients submitted to radical prostatectomy

Nowadays, optimize oncologic results and minimize the negative impact of local and systemic treatments on quality of life of patients with prostate cancer guide the way the treatment of prostate cancer is carried out. Since 2006, our group has partnered with leading authors of the most used patient-related outcomes questionnaires in prostate cancer. We have followed the international standardized translational process, cultural adaptation and pilot-test for the Brazilian version of the UCLA-PCI® and the EORTC QLQ-PR25® (1). The projects were approved by the both Ethics Committees. We read with interest the recently published paper regarding the Brazilian version of the EPIC® questionnaire (2). We support Alves et al. efforts in the improvement of the quality of life research in our country, with its known socio-cultural heterogeneity. There is, however, a missed step to complete the validation of the EPIC® questionnaire. The psychometrics properties are: reliability, validity and responsiveness. Reliability is important to measure score consistency, but it doesn’t guarantee the validation of a questionnaire (3). Furthermore, the EPIC® and the UCLA-PCI® should be scored in association with the core instrument (Rand SF-36® V2). The SF-36® is copyright and the researcher must pay royalties and user fees to QualityMetry® in order to use with the PCI and EPIC. The European Organization for Research and Treatment of Cancer, Quality of Life Group (EORTC QoL) offer the core instrument (EORTC C-30®), the cancer-specific module PR25® and the scoring manuals free of charge for academic non-sponsored projects (http://groups.eortc.be/qol/). The PR25® is composed by two functional scales (sexual activity and sexual functioning) and 4 symptoms scales (urinary symptoms, bowel symptoms, hormone treatment-related symptoms and incontinence aid). The sexual functioning scale is conditional on being sexually active and the incontinence aid is a conditional scale that must be answered only by patients using pads. Using a structured interview, we report here the internal consistency of the Brazilian version of the PR25® applied to 186 prostate cancer patients regardless if local or metastatic tumors. All patients enrolled were treated at two reference centers located in south of Brazil, with different cultural background (Santa Casa de Porto Alegre in Porto Alegre/RS and Centro de Pesquisas Oncológicas/CEPON in Florianópolis/SC). The overall internal consistency of the PR25 was measured using the Cronbach’s Vol. 41 (3): 604-605, May June, 2015